Vertex bags CHMP Positive Opinion for Kalydeco in EU
If approved, Kalydeco (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age.